Could a bladder pill help prevent diabetes?
NCT ID NCT04666636
First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether mirabegron, a drug currently used for overactive bladder, can improve glucose tolerance and activate brown fat in people with prediabetes. Researchers will enroll 65 adults with a BMI of 27-45 and prediabetes. Participants will take mirabegron or a placebo daily for 16 weeks, and the study will measure changes in blood sugar, body composition, and metabolism.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mirabegron (Myrbetriq)
- What this could lead to
- If it works, this could point toward a new treatment for prediabetes that improves blood sugar control and metabolism.
- What could go wrong
- This is a small, early-phase trial with only 65 participants. The drug is already approved for overactive bladder, but its effect on prediabetes is unproven, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREDIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kentucky
RECRUITINGLexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new rice could tame blood sugar spikes in prediabetes
- Could everyday supplements turn back the clock on aging?
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?
- Could a daily glass of milk help ward off type 2 diabetes?
- Can one avocado a day sharpen the aging brain?